Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Video navigation menu
- Is there an end to LDL-c lowering mediated risk reduction? 00:51
- Relevance of inflammation in chronic kidney disease 06:08
- Relevance of inflammation in diabetes mellitus type II 08:14
- Inflammation as therapeutic target: the CANTOS trial 09:34
- The role of epigenetics in developing anti-inflammatory interventions 11:32
This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.
Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: